Product Information
NRC-2694 is a novel anilino-based oral solid formulation for the treatment of bladder cancer. NRC-2694 is designed to inhibit the growth of cells in the bladder by binding to them and preventing their division. This drug has shown a safety profile in animal studies and has been shown to be active against squamous cell carcinomas in mice. The drug was also tested in vivo with bioavailability data in rats, showing that it is absorbed through the gastrointestinal tract and distributed throughout the body.
Chemical properties
Technical inquiry about: 3D-LMB44661 NRC-2694
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
